Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study

Anton Hagenbeek; Hans Mooij; Josée Zijlstra; Pieternella Lugtenburg; Gustaaf van Imhoff; Marcel Nijland; Sanne Tonino; Martin Hutchings; Marjolein Spiering; Roberto Liu; Harm van Tinteren; Marie José Kersten

doi:10.3324/haematol.2018.196899

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study

Anton Hagenbeek, Hans Mooij, Josée Zijlstra, Pieternella Lugtenburg, Gustaaf van Imhoff, Marcel Nijland, Sanne Tonino, Martin Hutchings, Marjolein Spiering, Roberto Liu, Harm van Tinteren, Marie José Kersten

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	e151-e153
Journal	Haematologica
Volume	104
Issue number	4
Early online date	31 Oct 2018
DOIs	https://doi.org/10.3324/haematol.2018.196899 https://doi.org/10.3324/haematol.2018.196899
Publication status	Published - 31 Mar 2019

Access to Document

Cite this

Hagenbeek, A., Mooij, H., Zijlstra, J., Lugtenburg, P., van Imhoff, G., Nijland, M., Tonino, S., Hutchings, M., Spiering, M., Liu, R., van Tinteren, H., & Kersten, M. J. (2019). Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study. Haematologica, 104(4), e151-e153. https://doi.org/10.3324/haematol.2018.196899, https://doi.org/10.3324/haematol.2018.196899

@article{9c2f5aac21dd49618ac4f71fde468c09,

title = "Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study",

author = "Anton Hagenbeek and Hans Mooij and Jos{\'e}e Zijlstra and Pieternella Lugtenburg and {van Imhoff}, Gustaaf and Marcel Nijland and Sanne Tonino and Martin Hutchings and Marjolein Spiering and Roberto Liu and {van Tinteren}, Harm and Kersten, {Marie Jos{\'e}}",

note = "Copyright {\textcopyright} 2018, Ferrata Storti Foundation.",

year = "2019",

month = mar,

day = "31",

doi = "10.3324/haematol.2018.196899",

language = "English",

volume = "104",

pages = "e151--e153",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "4",

}

Hagenbeek, A, Mooij, H, Zijlstra, J, Lugtenburg, P, van Imhoff, G, Nijland, M, Tonino, S, Hutchings, M, Spiering, M, Liu, R, van Tinteren, H & Kersten, MJ 2019, 'Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study', Haematologica, vol. 104, no. 4, pp. e151-e153. https://doi.org/10.3324/haematol.2018.196899, https://doi.org/10.3324/haematol.2018.196899

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma : The HOVON/LLPC transplant brave study. / Hagenbeek, Anton; Mooij, Hans; Zijlstra, Josée et al.

In: Haematologica, Vol. 104, No. 4, 31.03.2019, p. e151-e153.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma

T2 - The HOVON/LLPC transplant brave study

AU - Hagenbeek, Anton

AU - Mooij, Hans

AU - Zijlstra, Josée

AU - Lugtenburg, Pieternella

AU - van Imhoff, Gustaaf

AU - Nijland, Marcel

AU - Tonino, Sanne

AU - Hutchings, Martin

AU - Spiering, Marjolein

AU - Liu, Roberto

AU - van Tinteren, Harm

AU - Kersten, Marie José

PY - 2019/3/31

Y1 - 2019/3/31

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063979631&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30381303

U2 - 10.3324/haematol.2018.196899

DO - 10.3324/haematol.2018.196899

M3 - Letter

C2 - 30381303

SN - 0390-6078

VL - 104

SP - e151-e153

JO - Haematologica

JF - Haematologica

IS - 4

ER -

Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M et al. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study. Haematologica. 2019 Mar 31;104(4):e151-e153. Epub 2018 Oct 31. doi: 10.3324/haematol.2018.196899, 10.3324/haematol.2018.196899

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical hodgkin lymphoma: The HOVON/LLPC transplant brave study

Access to Document

Other files and links

Cite this